Comparative Pharmacology
Head-to-head clinical analysis: BIPHETAMINE 12 5 versus BIPHETAMINE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIPHETAMINE 12 5 versus BIPHETAMINE 7 5.
BIPHETAMINE 12.5 vs BIPHETAMINE 7.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biphetamine 12.5 is a central nervous system stimulant that increases the levels of norepinephrine and dopamine in the synaptic cleft by inhibiting the reuptake of these neurotransmitters and by promoting their release from presynaptic terminals.
Biphetamine 7.5 is a combination of amphetamine enantiomers (dextroamphetamine and levoamphetamine) that increase synaptic concentrations of dopamine and norepinephrine by inhibiting presynaptic reuptake and promoting release into the synaptic cleft.
12.5 mg orally once daily in the morning, may titrate weekly by 12.5 mg to maximum 75 mg/day.
Initial 7.5 mg orally once daily in the morning, titrated based on response and tolerability. Maximum daily dose is 30 mg.
None Documented
None Documented
9-14 hours in children and adolescents; clinical effects typically last 4-6 hours due to distribution and tolerance. Terminal half-life may be longer in adults with higher body fat (up to 20 hours).
6-8 hours (amphetamine moiety), 10-13 hours (dextroamphetamine); clinical effects may outlast serum levels due to accumulation.
Renal: 70-80% as unchanged drug and metabolites (primarily deaminated metabolites); fecaroute is negligible. Urinary pH-dependent: acidification increases renal clearance, alkalinization decreases it.
Renal: ~70-90% unchanged and as active metabolites; minor fecal elimination. Acidic urine (pH <5.6) increases excretion; alkaline urine (pH >7.0) decreases it.
Category C
Category C
Central Nervous System Stimulant
Central Nervous System Stimulant